Security Snapshot

LIFECORE BIOMEDICAL, INC. \DE\ - Common Stock (LFCR) Institutional Ownership

CUSIP: 514766104

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

102

Shares (Excl. Options)

24,790,192

Price

$8.18

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
LFCR on Nasdaq
Shares outstanding
37,508,353
Price per share
$4.94
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
24,790,192
Total reported value
$202,785,326
% of total 13F portfolios
0%
Share change
+389,068
Value change
+$3,377,781
Number of holders
102
Price from insider filings
$4.94
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • LFCR - LIFECORE BIOMEDICAL, INC. \DE\ - Common Stock is tracked under CUSIP 514766104.
  • 102 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 102 to 41 between Q4 2025 and Q1 2026.
  • Reported value moved from $202,785,326 to $9,277,055.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 102 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 514766104?
CUSIP 514766104 identifies LFCR - LIFECORE BIOMEDICAL, INC. \DE\ - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of LIFECORE BIOMEDICAL, INC. \DE\ - Common Stock (LFCR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Greenhaven Road Investment Management, L.P. 9.8% +25% $22,998,689 +$7,944,848 3,616,146 +53% Greenhaven Road Investment Management, L.P. 31 Dec 2024
22NW Fund, LP 7.5% -33% $20,768,278 -$9,716,865 2,975,398 -32% 22NW Fund, LP 27 May 2025
BlackRock, Inc. 5% -2.4% $6,949,021 -$118,998 1,867,916 -1.7% BlackRock, Inc. 31 Mar 2026
David Capital Partners, LLC 4.9% $11,467,080 1,803,000 David Capital Partners, LLC 31 Dec 2024

As of 31 Dec 2025, 102 institutional investors reported holding 24,790,192 shares of LIFECORE BIOMEDICAL, INC. \DE\ - Common Stock (LFCR). This represents 66% of the company’s total 37,508,353 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of LIFECORE BIOMEDICAL, INC. \DE\ - Common Stock (LFCR) together control 63% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
WYNNEFIELD CAPITAL INC 13% 4,703,216 0% 22% $38,472,306
Legion Partners Asset Management, LLC 12% 4,461,823 0% 21% $36,497,712
Greenhaven Road Investment Management, L.P. 9.8% 3,682,573 -0.33% 13% $30,123,447
325 CAPITAL LLC 5.8% 2,162,466 0% 6.2% $17,688,972
BlackRock, Inc. 5.1% 1,907,084 +3.6% 0% $15,599,947
VANGUARD GROUP INC 4.5% 1,673,666 +3.1% 0% $13,690,589
GEODE CAPITAL MANAGEMENT, LLC 2.1% 779,642 +0.78% 0% $6,379,153
MORGAN STANLEY 2% 751,505 +5.9% 0% $6,147,315
GRIZZLYROCK CAPITAL, LLC 2% 743,241 +0.59% 4.6% $6,079,711
STATE STREET CORP 1.6% 585,386 +8.5% 0% $4,788,457
DCF Advisers, LLC 1.2% 442,000 -2.2% 1.2% $3,615,560
MILLENNIUM MANAGEMENT LLC 0.67% 251,705 +86% 0% $2,058,947
Quinn Opportunity Partners LLC 0.65% 242,670 +32% 0.09% $1,985,041
NORTHERN TRUST CORP 0.6% 224,952 -5.7% 0% $1,840,108
TOCQUEVILLE ASSET MANAGEMENT L.P. 0.4% 151,700 0% 0.02% $1,240,906
JANE STREET GROUP, LLC 0.32% 119,445 +80% 0% $977,060
Diametric Capital, LP 0.31% 117,591 +356% 0.26% $961,894
LPL Financial LLC 0.3% 112,790 -24% 0% $922,622
MARSHALL WACE, LLP 0.29% 110,621 -3% 0% $904,882
Squarepoint Ops LLC 0.29% 110,499 -27% 0% $903,882
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.27% 99,881 +160% 0% $817,027
GOLDMAN SACHS GROUP INC 0.25% 93,651 +69% 0% $766,065
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.23% 87,713 +0.03% 0% $717,492
GAMCO INVESTORS, INC. ET AL 0.22% 83,800 -0.83% 0.01% $685,484
GSA CAPITAL PARTNERS LLP 0.22% 82,794 0.06% $677,000

Institutional Holders of LIFECORE BIOMEDICAL, INC. \DE\ - Common Stock (LFCR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 2,493,792 $9,277,055 +$667,880 $3.72 41
2025 Q4 24,790,192 $202,785,326 +$3,377,781 $8.18 102
2025 Q3 24,334,820 $179,104,999 -$442,653 $7.36 99
2025 Q2 24,384,958 $198,008,217 +$13,339,387 $8.12 84
2025 Q1 22,755,067 $160,201,265 -$2,326,304 $7.04 85
2024 Q4 23,042,098 $171,205,266 +$31,378,307 $7.43 74
2024 Q3 18,933,619 $93,344,132 +$959,877 $4.93 80
2024 Q2 18,597,383 $95,407,619 -$6,051,109 $5.13 73
2024 Q1 21,527,122 $114,309,004 +$1,281,084 $5.31 75
2023 Q4 21,214,493 $131,315,483 +$7,746,225 $6.19 77
2023 Q3 17,649,982 $132,309,917 -$4,239,641 $7.54 67
2023 Q2 17,960,139 $173,672,855 -$23,585,436 $9.67 73
2023 Q1 21,626,729 $81,665,566 -$19,155,973 $3.78 79
2022 Q4 24,699,229 $160,060,929 -$420,882 $6.48 92
2022 Q3 24,756,452 $220,096,095 -$5,076,219 $8.89 84
2022 Q2 25,281,897 $252,055,903 -$4,813,620 $9.97 86
2022 Q1 23,496,502 $272,006,071 -$4,453,715 $11.58 94
2021 Q4 25,875,011 $287,157,179 +$3,096,368 $11.10 95
2021 Q3 25,537,059 $235,449,630 +$11,336,792 $9.22 91
2021 Q2 25,595,693 $287,942,521 -$5,835,307 $11.25 95
2021 Q1 25,969,624 $275,201,016 -$6,203,031 $10.60 92
2020 Q4 26,546,714 $288,027,507 -$1,865,390 $10.85 95
2020 Q3 27,293,895 $265,303,644 +$8,398,552 $9.72 95
2020 Q2 26,759,176 $213,024,082 -$2,393,394 $7.96 91
2020 Q1 27,069,384 $235,223,542 -$2,453,651 $8.69 87
2019 Q4 27,094,595 $306,434,334 +$278,864 $11.31 92
2019 Q3 26,498,684 $287,625,125 -$10,583,915 $10.87 102
2019 Q2 27,497,586 $257,653,097 +$10,011,387 $9.37 98
2019 Q1 26,312,887 $323,120,159 +$5,328,462 $12.28 90
2018 Q4 25,883,944 $306,456,062 -$563,058 $11.84 88
2018 Q3 25,680,348 $367,065,569 -$2,817,222 $14.40 89
2018 Q2 25,073,308 $373,595,030 -$6,657,193 $14.90 89
2018 Q1 26,316,857 $343,465,751 +$5,904,468 $13.05 88
2017 Q4 25,838,571 $325,371,521 -$304,837 $12.60 90
2017 Q3 25,804,476 $334,160,959 +$6,036,656 $12.95 92
2017 Q2 25,319,960 $375,969,466 +$3,371,779 $14.85 92
2017 Q1 25,099,442 $301,208,568 +$26,792,518 $12.00 83
2016 Q4 24,664,192 $340,389,514 -$4,315,145 $13.80 91
2016 Q3 25,035,867 $335,724,442 -$8,276,505 $13.41 90
2016 Q2 25,716,341 $276,698,218 +$13,954,300 $10.76 92
2016 Q1 25,062,413 $263,156,774 +$7,503,955 $10.50 91
2015 Q4 24,362,954 $288,513,037 +$6,283,639 $11.83 106
2015 Q3 23,756,250 $277,238,057 -$6,250,112 $11.67 108
2015 Q2 24,236,757 $349,729,789 -$429,367 $14.43 107
2015 Q1 24,035,177 $335,230,454 -$392,081 $13.95 97
2014 Q4 24,080,381 $332,562,030 -$1,269,800 $13.81 105
2014 Q3 24,257,148 $294,986,600 +$2,810,099 $12.25 105
2014 Q2 23,981,587 $299,475,311 +$4,217,262 $12.49 99
2014 Q1 23,665,087 $264,250,906 -$9,506,174 $11.16 96
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .